Recombinant Anti-CD37 x Anti-CD64 Bispecific Antibody (scFv4-Ig) is an appended IgG format, which includes four scFv moieties at the N-termini of the constant regions. It is a bivalent homodimer, in which one anti-CD37 scFv is fused to the CH1 domain of a heavy chain and another anti-CD64 scFv to the CL domain of a light chain, or vice versa. The resulting leads to 2+2 antigen-binding valency. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Non-Hodgkin's lymphoma (NHL); Diffuse large B cell lymphoma (DLBCL); Chronic lymphocytic leukemia (CLL) therapy.